Study wrapper · #1059
Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.
Editor's note
A secondary, post hoc analysis of the phase 3a REDEFINE 1 trial examining anthropometric target attainment across CagriSema, its individual components, and placebo. As a post hoc analysis of a secondary endpoint, it is hypothesis-generating rather than confirmatory, but the underlying randomization and clear dose-ordered separation lend weight to the signal. Readers can read the results as support for target-based obesity management and for the combination's added anthropometric effect over its components.
Plain-language abstract
This post hoc analysis of the 68-week REDEFINE 1 obesity trial found that CagriSema (cagrilintide plus semaglutide) helped more participants reach stringent BMI and waist-to-height anthropometric targets than semaglutide or cagrilintide alone or placebo. Both BMI and waist-to-height ratio tracked similarly with cardiometabolic normalization.